Structure Therapeutics (NASDAQ:GPCR) Upgraded by Wall Street Zen to Sell Rating

Wall Street Zen upgraded shares of Structure Therapeutics (NASDAQ:GPCR) from a strong sell rating to a sell rating in a research note released on Monday.

Other analysts have also issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Friday, July 17th. Canaccord Genuity Group set a $111.00 price objective on Structure Therapeutics in a research report on Friday, August 7th. Citizens Jmp decreased their price objective on Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research report on Friday, August 7th. HC Wainwright lowered their target price on Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Citigroup restated a “market outperform” rating on shares of Structure Therapeutics in a research report on Friday, August 7th. Three research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Structure Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Trading Down 1.4%

GPCR opened at $53.76 on Monday. The stock has a market capitalization of $3.74 billion, a PE ratio of -53.76 and a beta of -1.43. Structure Therapeutics has a 1-year low of $18.26 and a 1-year high of $94.90. The firm has a 50-day moving average price of $49.54 and a two-hundred day moving average price of $52.38.

Structure Therapeutics (NASDAQ:GPCR) last announced its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, research analysts predict that Structure Therapeutics will post -1.84 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC boosted its stake in Structure Therapeutics by 18.5% in the second quarter. Geode Capital Management LLC now owns 54,181 shares of the company’s stock valued at $1,124,000 after acquiring an additional 8,444 shares during the last quarter. Invesco Ltd. grew its holdings in Structure Therapeutics by 7.6% during the 2nd quarter. Invesco Ltd. now owns 424,548 shares of the company’s stock worth $8,805,000 after acquiring an additional 30,162 shares during the period. Marshall Wace LLP raised its position in shares of Structure Therapeutics by 474.9% during the 2nd quarter. Marshall Wace LLP now owns 176,060 shares of the company’s stock valued at $3,651,000 after acquiring an additional 145,434 shares during the last quarter. Jump Financial LLC raised its position in shares of Structure Therapeutics by 105.9% during the 2nd quarter. Jump Financial LLC now owns 63,234 shares of the company’s stock valued at $1,311,000 after acquiring an additional 32,524 shares during the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in shares of Structure Therapeutics in the 2nd quarter valued at $3,480,000. 91.78% of the stock is owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.